Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Head & Neck 6Breast 3Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 200pembrolizumab 166Pemetrexed 139Cisplatin 124Paclitaxel 77durvalumab 73osimertinib 68Nivolumab 67Docetaxel 65Specimen Handling 64atezolizumab 57Magnetic Resonance Spectroscopy 53Gemcitabine 46Etoposide 46Radiotherapy 42Radiosurgery 38130-nm albumin-bound paclitaxel 34Drug Therapy 32Bevacizumab 29Ipilimumab 27Cetuximab 27cemiplimab 24Taxes 24tislelizumab 21Immunoglobulin G 21Platinum 20Biopsy 20amivantamab 19Radiation 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
camrelizumab × Thoracic × 90 days × Clear all
NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Guangdong Association of Clinical Trials

Phase 3 Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡